Introduction：Basic information about CAS 1446502-11-9|Enasidenib, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Enasidenib |
|---|
| CAS Number | 1446502-11-9 | Molecular Weight | 473.375 |
|---|
| Density | 1.5±0.1 g/cm3 | Boiling Point | 581.0±60.0 °C at 760 mmHg |
|---|
| Molecular Formula | C19H17F6N7O | Melting Point | / |
|---|
| MSDS | / | Flash Point | 305.2±32.9 °C |
|---|
Names
| Name | Enasidenib |
|---|
| Synonym | More Synonyms |
|---|
Enasidenib BiologicalActivity
| Description | Enasidenib is an oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes, with IC50s of 100 and 400 nM against IDH2R140Q and IDH2R172K, respectively. |
|---|
| Related Catalog | Signaling Pathways >>Metabolic Enzyme/Protease >>Isocitrate Dehydrogenase (IDH)Research Areas >>Cancer |
|---|
| Target | IC50: 100 nM (IDH2R140Q), 400 nM (IDH2R172K)[1] |
|---|
| In Vitro | Enasidenib (AG-221) reverses the effects of mutant IDH2 on DNA methylation in mutant stem/progenitor cells. Enasidenib induces differentiation and impairs self-renewal of IDH2-mutant leukemia cells, effects that are further enhanced by simultaneous inhibition of Flt3ITD. Enasidenib (AG-221) therapy induces differentiation of leukemic cells, with an increase in the CD11b+ population and a decrease in the c-Kit+ population in the peripheral blood at 2wks[2]. |
|---|
| In Vivo | Treatment with Enasidenib (AG-221) significantly improves survival in an IDH2-mutant acute myeloid leukemia (AML) primary xenograft mouse model[1]. Enasidenib (AG-221), a mutant IDH2 inhibitor, remodels the epigenetic state of IDH2-mutant cells and induces alterations in self-renewal/differentiation in IDH2-mutant AML model in vivo. Enasidenib treatment (10mg/kg or 100mg/kg bid) leads to a reduction in 2-HG in vivo (96.7% below pre-treatment levels). Moreover, Enasidenib treatment restores megakaryocyte-erythroid progenitor (MEP) differentiation that is suppressed by mutant IDH2 expression (mean MEP% mean, 39% Veh vs 50% AG-221). Enasidenib therapy reverses the effects of mutant IDH2; a significant reduction is observed in DNA methylation, including 180 genes that have 20 or more hypomethylated differentially methylated cytosines (DMCs) following treatment. Enasidenib (100mg/kg bid) treatment of mice engrafted with Mx1-Cre IDH2R140QFlt3ITD AML cells markedly reduces 2-hydroxyglutarate (2-HG) levels consistent with on target inhibition. Enasidenib inhibits mutant IDH2-mediated 2-HG production[2]. |
|---|
| References | [1]. Exploring the Pathway: IDH Mutations and Metabolic Dysregulation in Cancer Cells: A Novel Therapeutic Target. MAY 29, 2015 [2]. Alan H. Shih, et al. AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo. Blood 2014 124:437. |
|---|
Chemical & Physical Properties
| Density | 1.5±0.1 g/cm3 |
|---|
| Boiling Point | 581.0±60.0 °C at 760 mmHg |
|---|
| Molecular Formula | C19H17F6N7O |
|---|
| Molecular Weight | 473.375 |
|---|
| Flash Point | 305.2±32.9 °C |
|---|
| Exact Mass | 473.139862 |
|---|
| PSA | 108.74000 |
|---|
| LogP | 4.24 |
|---|
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
|---|
| Index of Refraction | 1.573 |
|---|
| InChIKey | DYLUUSLLRIQKOE-UHFFFAOYSA-N |
|---|
| SMILES | CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1 |
|---|
| Storage condition | -20℃ |
|---|
Synonyms
| AG-221 |
| 2-Methyl-1-[(4-[6-(trifluoromethyl)-2-pyridinyl]-6-{[2-(trifluoromethyl)-4-pyridinyl]amino}-1,3,5-triazin-2-yl)amino]-2-propanol |
| 2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol |
| CC-90007 |
| Enasidenib |
| UNII:3T1SS4E7AG |
| 2-Propanol, 2-methyl-1-[[4-[6-(trifluoromethyl)-2-pyridinyl]-6-[[2-(trifluoromethyl)-4-pyridinyl]amino]-1,3,5-triazin-2-yl]amino]- |
